Shearwood McClelland III, Director of Spine Oncology, Department of Radiation Oncology at University Hospitals, shared a post on X about his recent paper, commenting:
“Pleased to publish our piece regarding the Financial Toxicity associated with achieving progression-free survival based on the INDIGO trial with Michael Milano and Martin Tom!”
The Cost of Progression-Free Survival in Treating Low-Grade Glioma published in American Journal of Clinical Oncology.
